Antibodies
5 April 2007
Merck KGaA: Erbitux Meets Primary Endpoint in First-Line Phase III Head and Neck Cancer Study5 April 2007
Merck KGaA: Erbitux Meets Primary Endpoint in First-Line Phase III Head and Neck Cancer Study5 April 2007
Genzyme Files for Expanded Label for Campath(R) as First-Line Treatment for B-CLL Patients4 April 2007
Viventia Biotech initiates patient treatment for Vicinium(TM) Phase II bladder cancer trial4 April 2007
Pharmexa and Affitech enter into an exclusive license agreement to promote Diabody technology31 March 2007
Astellas Licenses Regeneron Velocimmune(R) Technology For Discovering Human Monoclonal Antibodies30 March 2007
NEOPHARM Reports on FDA Meeting30 March 2007
XTL Announces the Completion of Phase I Study with XTL-6865 in Patients with Chronic Hepatitis C29 March 2007
MorphoSys and Astellas Enter Antibody Partnership – Deal Seals MorphoSys’s Third Japanese Pharmaceutical Alliance29 March 2007
Avastin Approved in Europe for First Line Treatment of Women with Metastatic Breast Cance28 March 2007
Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration28 March 2007
Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech24 March 2007
MedImmune Expands Anti-Interferon-Alpha Program by Initiating Phase 1 Trial in Patients With PsoriasisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports